Home / Learn / Immunotherapy / View All IO Resources

View All IO Resources

Here is a comprehensive list of all of our immuno-oncology resources. Enter your search terms in the box below to filter your results.

Displaying results 41 - 60 of 120

Prev 1 2 3 4 5 6 Next
Experts from the Saint Agnes Cancer Institute in Baltimore, Maryland hosted an Institute for Clinical Immuno-Oncology (ICLIO) Visiting Experts workshop to accelerate their learning about managing patients being treated with immuno-oncology (I-O) agents.
July 16, 2018
View the archived webinar: CAR T-Cell Therapy for Your Patients: What You Need to Know with expert presenter, Marco L. Davila, MD, PhD, Medical Oncologist, H. Lee Moffitt Cancer Center & Research Institute Learn about the MOA of Chimeric Antigen Receptor T-cell (CAR-T) therapy and approved FDA indications, understand where CAR T-cell therapy fits into the oncology landscape…
Jeff Litiker, BCOP Clinical Oncology Pharmacy Manager, shares his perspective on best practices in pharmacy logistics, including inventory, dispensing, and storage.
Mounting evidence suggests that the gut microbiome (or microbiota) plays a fundamental role in the activation, regulation, and function of the immune system. There is ongoing interest in the relationship between the gut microbiome and cancer development.
November 13, 2017
Presenter: Vamsidhar Velcheti, MD, FACP, Staff Physician, Hematology and Oncology; Associate Director, Center for Immuno-Oncology Research Taussi Cancer Institute | Cleveland Clinic Immunotherapies are now standard of care for many tumor types. However, recognizing patients who would benefit the most from these therapies and patients at risk for developing immune-related adverse events (irAEs) re…
Patients undergoing cancer treatment need access to reliable information and cancer-related resources to provide education and support empowerment. This article provides an update to resources currently available for those undergoing treatment with immuno-oncology (I-O) agents.
This article provides an overview of hematologic malignancies; reviews how CAR T-cell therapies are made and work; discusses the approved CAR T-cell therapy as well as those still under development; and considers some of the unique challenges and concerns that may arise with CAR T-cell therapy in the treatment of patients with hematologic malignancies.
August 31, 2017
Presenter: Brent Hanks, MD, PhD, Assistant Professor of Medicine, Duke Cancer Institute The March 2017 FDA approval of avelumab, a PD-L1 checkpoint inhibitor, for patients with metastatic Merkel cell carcinoma (MCC) provides a new treatment option for this rare skin cancer. Review the current treatment algorithm and clinical evidence supporting immunotherapies in MCC patients. Learn about other i…
Rapid advances in immuno-oncology therapies have transformed the way oncologists approach managing patients across numerous solid tumor malignancies. This article focuses on some of the challenges the oncology community faces with these emerging immunotherapies.
To identify best practice ideas about how to implement an immunotherapy program, ICLIO talked with Una Hopkins, DNP, ‎Administrative Director of Dickstein Cancer Center at White Plains Hospital, New York.
ICLIO spoke with Lisa A. Kottschade, APRN, CNP, Associate Professor of Oncology, Division of Medical Oncology, the Mayo Clinic, Rochester, Minnesota, about recognizing and managing immune-related endocrine effects.
David S. Ettinger MD, FACP, FCCP has served on the ICLIO Advisory Board since its inception. Recently we spoke with Dr. Ettinger about his role in immuno-oncology (I-O) advocacy and his vision for ICLIO.
ICLIO recently spoke to Clara Lambert, Oncology Financial Navigator at the Cowell Family Cancer Center in Michigan, about the range of financial assistance options for patients with cancer.
As combination I-O becomes more prevalent, what is the cost and reimbursement outlook? How can cancer programs prepare to address these challenges and ensure access to these emerging treatment options?
August 31, 2017
View the archived ICLIO Webinar: Emerging Role of Immunotherapy in Metastatic Merkel Cell Carcinoma with expert presenter, Brent Hanks, MD, PhD, Assistant Professor of Medicine, Duke Cancer Institute. Watch WebinarDownload Slides The March 2017 FDA approval of avelumab, a PD-L1 checkpoint inhibitor, for patients with metastatic Merkel cell carcinoma (MCC) provides a new treatment option for t…
We recently spoke with Dr. Nair to learn more about his scholarship and experience in treating patients with I-O therapies.
As IHC-based biomarkers become part of the standard of care in selecting patients for PD-L1 checkpoint inhibitor therapy, the role of pathologists is expanding.
The number of treatment options for malignant melanoma continues to expand, with immunotherapy emerging as a fundamental component of patient care. This article provides an overview of the immune mechanisms of immunotherapy agents used in the treatment of melanoma, reviews common immune-related adverse events (irAEs) that are observed with the recently approved immuno-oncology checkpoint inhibitor…
June 27, 2017
Lee S. Schwartzberg, MD, FACP, Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West Clinic, PC Memphis, TN This presentation highlights the immuno-oncology updates from the 2017 ASCO Annual Meeting in Chicago, IL. View On-Demand WebinarDownload Slides
To explore the use and timing of biomarkers for immune checkpoint inhibitors, we spoke with Jimmy Ruiz, MD, Associate Professor of the Thoracic Oncology Program at Wake Forest Baptist Comprehensive Cancer Center in Winston-Salem, North Carolina.

Displaying results 41 - 60 of 120

Prev 1 2 3 4 5 6 Next